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a  b  s  t  r  a  c  t
Depression  is one  of  the  major  causes  of disability  worldwide,  but the  complete  etiology  of  depression
is  not  fully  understood.  Dehydroepiandrosterone  (DHEA)  and  its sulphated  form  DHEA(S) have  been
associated  with  mood  and  healthy  aging.  Associations  with  mental  illness  over  the  middle  to  late  years
of life  have  not  yet  been  extensively  investigated  in  large,  western  community-dwelling  samples.  The
aim of  this  study  was  to investigate  whether  low  DHEA(S)  levels  are associated  with  the  development
of  depressive  symptoms  in a  large  longitudinal  cohort  study  of  older  men  and  women.  We  assessed
data  from  English  Longitudinal  Study  of  Aging  (ELSA)  to evaluate  the  association  of DHEA(S)  levels  and
depressive  symptoms  measured  by  Center  for Epidemiologic  Studies  Scale  (CES-D)  at  baseline  (n =  3083)
and  at  4-year  follow-up  (n =  3009).  At  baseline,  there  was an  inverse  association  between  DHEA(S)  andging
sychological stress
iomarkers
depressive  symptoms  (B  = −0.252,  p = 0.014).  Adjustments  for physical  illnesses,  impairments  in cognitive
function  and  health  behaviors  abolished  this  association  (p = 0.109)  at baseline.  Decreased  DHEA(S)  levels
at  baseline  also  predicted  incident  depression  at 4-year  follow-up  (B =  −0.332,  p  < 0.001).  In conclusion,
higher  DHEA(S)  levels  were  associated  with  reduced  risk  of  developing  depressive  symptoms  in  both
men  and  women.
©  2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
Depression is the second major cause of disability worldwide
ffecting around 350 million people (WHO, 2009). Although the
recise etiology of depression is complex and remains unclear,
here is evidence that the prevalence of depressive disorder
ncreases with age (Samaras et al., 2013) and affects around 17%
f the elderly population (Luppa et al., 2010).
Dehydroepiandrosterone (DHEA) is a steroid hormone mainly
ynthesized in the adrenal glands in response to adrenocorti-
otrophic hormone, although de novo synthesis in the brain has also
een described (Maninger et al., 2009; Sugaya et al., 2015). DHEA
nd its sulphated form DHEA(S) are the more prevalent circulating
teroid hormones, acting as precursors of the sexual hormones, as
 neurosteroid, and it is hypothesised to present opposite effects to
∗ Corresponding author at: Department of Epidemiology and Public Health,
niversity College London, 1-19 Torrington Place, London WC1E 6BT, UK.
ax: +44 207 916 8542.
E-mail address: livia.a.carvalho@ucl.ac.uk (L.A. Carvalho).
ttp://dx.doi.org/10.1016/j.psyneuen.2015.11.005
306-4530/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
glucocorticoids (Maurice et al., 1996; Kimonides et al., 1999; Binello
and Gordon, 2003; Maninger et al., 2009; Moriguchi et al., 2013).
DHEA has been described as a modulator of neurotransmission as it
can affect serotonin, -amino butyric acid (GABA), glutamate, and
dopamine levels (Kimonides et al., 1998; Robichaud and Debonnel,
2004; Traish et al., 2011). Studies demonstrate that DHEA presents
a strong age-related decline (Berr et al., 1996; Kroboth et al., 1999),
and thus may  help explain age related increases in depression.
The role of DHEA(S) in depression is still poorly understood. In
clinically diagnosed depressed patients the role DHEA(S) plays is
still inconclusive, as studies showing increased (Assies et al., 2004;
Morita et al., 2014), decreased (Kurita et al., 2012; Lopes et al., 2012)
and no changed levels have been found (Erdinc¸ ler et al., 2004). In the
population, most cross-sectional studies report that lower DHEA(S)
levels are associated with poor mental health (Haren et al., 2007;
Wong et al., 2011; Michikawa et al., 2013) although no association
has also been reported (ó Hartaigh et al., 2012). The role of gender
on this association is still inconclusive (Berr et al., 1996; Michikawa
et al., 2013).
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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nFig. 1. Analytical sample ﬂowchart.
Few prospective studies have been conducted and are com-
aratively small in sample size or have analysed women  or men
xclusively. These studies seem to point toward an association of
ower DHEA(S) levels with incident depression (Berr et al., 1996;
oldman and Glei, 2007; Michikawa et al., 2013; Veronese et al.,
015). The aim of this study was to investigate whether lower
HEA(S) levels predicts the development of depressive symptoms
n a large community-dwelling sample of older men  and women.
. Methods
.1. Study population
The English Longitudinal Study of Aging (ELSA) is a longitudinal
tudy of men  and women aged 50 and over, and is representa-
ive of people living in England (Steptoe et al., 2013). Objective
nd subjective data relating to health and disability, biological
arkers of disease, economic circumstances, social participation,
etworks and well-being were collected. ELSA aims to measure
utcomes across a wide range of domains and to provide high-
uality multidisciplinary data that can shed light on the causes
nd consequences of outcomes of interest. Wave 1 was  col-
ected in 2002/3, and participants are followed-up every 2 years,
ith a nurse visit and biomarker assessment every four years
http://www.ifs.org.uk/ELSA). Participants gave full informed con-
ent to participate in the study and ethical approval was  obtained
rom the London Multi-center Research Ethics Committee. For the
urposes of the present analyses, data collected at wave 4 (2008/9)
ere used as the baseline.
For the present study, 10,601 people participated in the study.
ince 2008, 1788 people had died by 2013 follow-up period and
ere therefore not included in the analysis. 2309 were excluded
ue to missing depressive symptoms scores at baseline. More-
ver, 3421 participants were excluded because there were no
nformation about DHEA(S) and/or covariates. We  have excluded
articipants with doctor-diagnosed dementia. Thus, at baseline
here were 3083 people. Seventy-four participants did not have
ESD scores at follow-up. At follow-up the analytical sample con-
isted of 3009 participants eligible for analysis. Selection of the
nalytical sample is represented in Fig. 1.
Compared to those study members who featured in the ana-
ytical sample, people with missing data were more likely to
e female (X2 = 20.75, P < 0.001), smokers (X2 = 26.27, P < 0.001),
n the lowest tertile of wealth (X2 = 12.20, P < 0.001), to report
igher depressive symptoms (total sample 1.40 ± 1.90, analytical
.11 ± 1.70, p < 0.001), be inactive (X2 = 41.71, P < 0.001), and have
igher frequency of cognitive impairment (total score total sample
9.77 ± 6.99, analytical sample 31.21 ± 5.73, p < 0.001). However,
o more likely to have diabetes, cardiovascular disease, stroke orendocrinology 64 (2016) 40–46 41
cancer (X2 = 0.199, P = 0.348), be obese (X2 = 0.83, P = 0.402) or con-
sume alcohol (X2 = 4.337, P = 0.114).
2.2. Assessment of depressive symptoms
Depressive symptomatology was  measured using the eight-
item Center for Epidemiological Studies-Depression (CES-D) scale,
a widely used measure that identiﬁes people “at risk” of depression
in population surveys (Radloff, 1977; Turvey et al., 1999). The psy-
chometric values of the eight-item CES-D are comparable to those
of the full 20-item CES-D (Stefﬁck, 2000). We  derived a summary
CES-D score by adding responses to all eight dichotomous ques-
tions (possible range: 0–8). To exclude cases of elevated depressive
symptoms that are possible cases of clinical depression at base-
line, we dichotomized the summary score around the cut point of
four or higher, a conservative threshold that corresponds to the cut
point of 16 or higher on the 20-item CES-D (Stefﬁck, 2000) in our
longitudinal analysis.
2.3. Assessment of DHEA(S)
Blood samples were taken from willing ELSA core mem-
bers, except those who  had a clotting or bleeding disorder (e.g.,
hemophilia or low platelets), had ever had a ﬁt, were not willing
to give their consent in writing or were currently on anticoagulant
drugs (e.g., warfarin therapy).
DHEA(S) was only collected at baseline. The analysis of the blood
data was  carried out in the Royal Victoria Inﬁrmary (Newcastle-
upon-Tyne, UK). The analysis of DHEA(S) levels from serum was
performed using the Roche DHEA(S) assay that is a competitive
immunoassay using electrochemiluminescence technology (ana-
lytical range: 0.003–27 mol/L). During the ﬁrst incubation step
DHEA(S) binds with a biotinylated monoclonal DHEA(S)-speciﬁc
antibody. During the second incubation a DHEA(S) derivative
labeled with a ruthenium complex occupies the remaining free
binding sites on the biotinylated antibody. The entire complex
becomes bound to the streptavidin-coated microparticulate solid
phase via interaction of biotin and streptavidin. The reaction
mixture is aspirated in to the measuring cell where the micropar-
ticles are magnetically captured onto the surface of the electrode.
Unbound substances are removed using Procell. Application of a
voltage to the electrode induces chemiluminescent emission that
is measured by a photomultiplier. Results are determined by mea-
suring the electrochemiluminescence signal obtained from the
reaction product of the sample against a calibration curve gener-
ated by 2-point calibration and a master curve provided via the
reagent barcode. Detailed information on the technicalities of the
blood analysis, the internal quality control and the external qual-
ity assessment for the laboratory have been described elsewhere
(Graig et al., 2006).
2.4. Measurement of covariates
Participants’ age, gender and BMI  were assessed during a face-
to-face visit in the home. Height and weight, which were assessed
by a nurse, were used to calculate body mass index (BMI, kg/m2).
Socioeconomic status was  indexed by total household wealth,
including ﬁnancial wealth (savings and investments), the value of
any home and other property (less mortgage), the value of any busi-
ness assets and physical wealth such as artwork and jewelry, net
of debt. Wealth is the most robust indicator of socioeconomic cir-
cumstances in ELSA (Banks et al., 2003). Cohabitation was  deﬁned
as currently living alone or not. Cognitive function was  assessed
using a test of memory and executive function (Steel et al., 2003).
Self-reported health behaviors included smoking status (current,
ex-smoker/never), frequency of alcohol consumption in the past
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Table 1
Demographic characteristics of older men  and women at baseline.
Demographics
Age (yrs) (mean ± SD) 65.8 ± 8.7
Male/Female 46%/54%
Wealth (%)
Poorest tertile 34%
Tertile 2 20%
Richest tertile 45%
BMI  (kg/m2) (mean ± SD) 28.1 ± 4.9
Smoking status (%) current smoker 11%
Chronic illness (%) 16%
Physical exercise
Sedentary 2%
Low 10%
Moderate 52%
vigorous 36%
Alcohol consumption
Never 35%
Occasionally 48%
Daily 17%
Depression at baseline 11%
Depression at 4-year follow-up 10%
B
y
a
i
p
e
t
s
2
C
l
m
a
l
t
s
l
(
(
t
p
f
f
i
a
d
3
3
i
p
t
c
Table 2
DHEA(S) and depressive symptoms are negatively associated at baseline (n = 3083).
Current depressive symptoms B (95% CI) P-value
Model 1 −0.252 (−0.451, −0.052) 0.014
Model 2 −0.233 (−0.431, −0.035) 0.021
Model 3 −0.200 (−0.397, −0.002) 0.047
Model 4 −0.185 (−0.382, 0.013) 0.067
Model 5 −0.160 (−0.357,−0.036) 0.109
B = unstandardized beta; CI = conﬁdence interval.
DHEA(S) = dehydroepiandrosterone-sulphate. Model 1 = DHEA(S), age, sex,
antidepressant use, cohabitation status. Model 2 = In addition to model 1, adjust-
ment for wealth. Model 3 = In addition to model 2, adjustment for cognitive
impairment. Model 4 = In addition to model 3, adjustment for chronic illness. ModelDHEA(S) (mol/L) (mean ± SD) 2.41 ± 1.80
MI  = body mass index; DHEA(S) = dehydroepiandrosterone sulphate.
ear (rarely (<1 week), occasionally (>1/week), frequently (>1/day),
nd physical activity during leisure time, recorded as participation
n vigorous, moderate, mild or sedentary activities (more than once
er week, once per week, 1–3 times per month, hardly ever) (Hamer
t al., 2009). Chronic illness was assessed as self-reported doc-
or diagnosed diabetes mellitus (self-report or medication), cancer,
troke, and cardiovascular diseases (“Yes”/”No”).
.5. Statistical analysis
All analyses were conducted using SPSS, version 22 (SPSS Inc.,
hicago IL). We  normalized the distribution of DHEA(S) by natural
ogarithmic transformation and used linear regression to esti-
ate standardized multinomial linear regression coefﬁcient (B)
nd 95% conﬁdence interval (CI) for depressive symptoms at base-
ine (2008/9). We  treated DHEA(S) as continuous variable. To assess
he association between the log of the mean DHEA(S) and depres-
ive symptoms at 4-year follow-up, we performed multinomial
inear regression analysis of the CES-D scores at 4-year follow-up
2012/13) with adjustment for depressive symptoms at baseline
2008/9). To further explore persistent depressive symptoms over
he 4 years (2008/9–2012/2013), multinomial logistic analysis were
erformed using the CES-D scores (>4) at baseline and at 4-year
ollow-up. We  estimated unadjusted models that were adjusted
or age, sex, marital status, antidepressant use, wealth, cognitive
mpairment, smoking status, BMI, alcohol consumption, physical
ctivity and history of chronic illnesses (cardiovascular disease,
iabetes, stroke and cancer).
. Results
.1. Demographic characteristics
Table 1 represents information on socio-demographic and clin-
cal characteristics of the 3083 participants at baseline. Fifty four
ercent of the study sample were women. The majority of par-
icipants were at the richest tertile, most people did not smoke,
onsume alcohol occasionally, conducted vigorous physical activity5  = In addition to model 4, adjustment for smoking status, physical activity, alcohol
consumption and BMI.
once a week. Eleven percent of people were depressed at baseline,
and 10% at 4-years follow-up.
3.2. DHEA(S) and depressive symptoms are negatively associated
at baseline
To determine whether there was a cross-sectional relationship
between serum levels of DHEA(S) and current depressive symp-
toms, we performed linear regression analysis between DHEA(S)
(log-transformed continuous values) with CES-D scores at baseline.
DHEA(S) was 17% lower in people with high depressive symp-
toms compared to those with low depressive symptoms. In our
basic model, we  corrected for age and gender at baseline. Subse-
quently, corrections for socio-demographic, health characteristics
and health behaviors were performed. There was an associa-
tion between DHEA(S) and depressive symptoms at baseline after
adjustment for socio-demographic factors. However, the associa-
tion was attenuated and became non-signiﬁcant (p = 0.109) after
corrections for all potential confounders were considered (Table 2).
There was no interaction between DHEA(S) and gender in
our analysis. However, as previous studies have found associa-
tions of DHEA(S) and depressive symptoms to be gender-speciﬁc
we have conducted these associations separately in men  and
women and added this information in Supplementary tables.
In our study, women had signiﬁcantly lower levels of DHEA(S)
(men = 3.09 ± 2.06 versus women = 1.84 ± 1.29, p < 0.001). At base-
line, despite the association in men  (but not in women) in our basic
model (p = 0.015), there was no association between DHEA(S) nei-
ther in men  (p = 0.187, Supplementary Table 1A) nor in women
(p = 0.239, Supplementary Table 1B) when all potential confounders
were considered.
3.3. Low DHEA(S) levels predict depressive symptoms at 4-year
follow-up
To investigate whether DHEA(S) levels are associated with
future depressive symptoms at 4-year follow-up, linear regressions
were performed with CES-D scores at 4-year follow-up. One hun-
dred and sixty four new cases of depression were detected. Those
who developed depression had 19% lower DHEA(S) levels com-
pared to those who  did not develop depression. In our basic model,
we corrected for age, gender and depressive symptoms at base-
line. Subsequently, corrections included socio-demographic, health
characteristics (B = −0.331, CI −0.518, −0.145, p = 0.001) and health
behaviors. Adjustment for health characteristics or health behav-
iors (B = −0.332, CI −0.520, −0.145, p = 0.001) did not modify the
association between DHEA(S) and depressive symptoms (Table 3).
When stratiﬁed by gender, DHEA(S) was associated with future
development of depressive symptoms at 4-year follow-up in men
L.H. Souza-Teodoro et al. / Psychoneuro
Table  3
Low DHEA(S) levels predict depressive symptoms at 4-year follow-up (n = 3009).
Incident depressive symptoms B (95% CI) P-value
Model 1 −0.338 (−0.525, −0.152) <0.001
Model 2 −0.333 (−0.519, −0.147) <0.001
Model 3 −0.328 (−0.514, −0.142) 0.001
Model 4 −0.331 (−0.518, −0.145) 0.001
Model 5 −0.332 (−0.520, −0.145) 0.001
B = unstandardized beta; CI = conﬁdence interval.
DHEA(S) = dehydroepiandrosterone-sulphate. Model 1 = DHEA(S), age, sex,
antidepressant use, cohabitation status. Model 2 = In addition to model 1, adjust-
ment for wealth. Model 3 = In addition to model 2, adjustment for cognitive
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wmpairment. Model 4 = In addition to model 3, adjustment for chronic illness. Model
 = In addition to model 4, adjustment for smoking status, physical activity, alcohol
onsumption and BMI.
p = 0.004, Supplementary Tables 2A) and in women (p = 0.025, Sup-
lementary Table 2B).
.4. Exploratory analysis
DHEA(S) has been previously observed to decline in those who
ave a persistent major depressive episode (Mocking et al., 2015).
e have ran a nominal regression to investigate whether people
ith lower levels of DHEA(S) were at higher risk of having higher
epressive symptoms at both waves, compared to having depres-
ion at only one wave or none. Our data showed that people who
ad persistent depression did not have lower levels of DHEA(S),
hen compared to people who did not have persistent depression
−0.078%, B = −0.393, CI 0.354,−1.287, p = 0.233).
We  also explored whether people who took antidepressants had
ifferent DHEA(S) levels, than people who did not take antidepres-
ants in the past two years. Levels of DHEA(S) did not differ between
hose who had or not taken antidepressants in the past two
ears (Yes, n = 98, 2.25 ± 1.64 versus No, n = 2985, 2.41 ± 1.8 mol/L,
 = 0.445 respectively). Between those who were on antidepres-
ants, DHEA(S) levels also did not differ whether people had low
r high depressive symptoms (low n = 60, 2.32 ± 0.25, high n = 38,
.33 ± 0.22, p = 0.52).
. Discussion
In this large longitudinal cohort study we demonstrated that low
evels of DHEA(S) predicts future depressive symptoms in both men
nd women. In our analyses, the longitudinal associations observed
etween DHEA(S) and depressive symptoms were independent of
ge, gender, economic circumstances and health behaviors and
haracteristics.
.1. DHEA(S) levels and depressive symptoms
Our study is the largest to date to investigate the relation-
hip between DHEA(S) and future depressive symptoms in a
ommunity-dwelling sample of both men  and women. The lon-
itudinal ﬁndings of our study are supported by other smaller
rospective studies that showed lower DHEA(S) levels associated
o poor mental health. A recent paper reported higher DHEA(S)
evels to be protective for the onset of depression irrespective of
ender (Veronese et al., 2015). In their study, DHEA(S) was  also
nversely associated with incident severe depression but this asso-
iation was exclusively observed in men  (Veronese et al., 2015). In
ur study severity of depressive symptoms could not be assessed
s we only used a brief depressive symptoms questionnaire and
herefore results cannot be directly comparable. Mazat et al. (2001)
ound an association between DHEA(S) levels and mortality in men
ho smoke, and an association with depressive symptomatologyendocrinology 64 (2016) 40–46 43
in women. Other studies that have investigated DHEA(S) and inci-
dent depressive symptoms found it to be gender speciﬁc (in men,
Michikawa et al., 2013) (in women Yaffe et al., 1998; Mazat et al.,
2001). In addition, there are reports of no longitudinal association
in either gender (ó Hartaigh et a., 2012). Herein, we did not ﬁnd
DHEA(S) and gender interaction in the association with depression.
Explanations for differences in the association related to gender are
debatable and not yet clear.
DHEA(S) was  inversely associated with current depressive
symptoms cross-sectionally in the basic model, but adjustment
for chronic illness and health behaviors abolished the association.
When compared to other population studies, our study agrees with
others who showed no association of DHEA(S) and depression at
baseline (Erdinc¸ ler et al., 2004; T’sjoen et al., 2005; Hsu et al.,
2009; ó Hartaigh et al., 2012). The role of DHEA(S) in depression
is still unclear as inverse associations have also been reported in
the population (Wong et al., 2011; Michikawa et al., 2013). In clin-
ically diagnosed depressed patients, a large cross-sectional study
also did not ﬁnd an association (Phillips et al., 2011). In contrast, a
recent cross-sectional meta-analysis conﬁrmed ﬁndings of a lower
DHEA(S) in people with clinical major depression, however, adjust-
ment for ethnicity abolished the association in Caucasians (Hu et al.,
2015). The explanation why  we only found longitudinal associa-
tions is not clear. It is possible that persistently low DHEA(S) is
inﬂuencing the aging process so those with low DHEA(S) at baseline
experience greater declines over the follow-up e.g., in frailty over
and above their chronic diseases and lifestyle, leading to greater
depressive symptoms. Indeed, Mazat et al. (2001) has measured
DHEA(S) overtime in the population and shown a bigger impact
on health associated with greater DHEA(S) decline. Moreover, as
DHEA(S) declines with age (Kroboth et al., 1999), it is possible that
that lower levels of DHEA(S) become more predominant and detri-
mental to physical and mental health as one ages (Berr et al., 1996;
Bauer, 2005; Buford and Willoughby, 2008). Low DHEA(S) has also
been associated with poor physical illness (Berr et al., 1996). It is
thus possible that people who had lower levels of DHEA at base-
line developed more physical illnesses, which then led them to
experience more depressive symptoms at follow up.
In our exploratory analysis, we  did not ﬁnd an association
between DHEA(S) and persistent depression. This association was
contrary to a recent study which demonstrated how DHEA(S)
remains equally altered between episodes and may  predict future
recurrence (Mocking et al., 2015). Our study differs from that of
Mocking et al. (2015), who have used a clinical patient group of peo-
ple with a major depression diagnosis, whilst we  used a population
cohort. The difference in population may  explain the confound-
ing results. It is also possible that we did not ﬁnd an association
with persistent depression due to the low number of people in
our group (only 178 people). Among clinically depressed patients,
DHEA(S) role remains unclear as no changed (Erdinc¸ ler et al., 2004),
increased (Assies et a., 2004; Morita et a., 2014) or decreased (Lopes
et al., 2012) levels have been reported.
4.2. Sex differences
An interaction between gender and DHEA(S) was  not found
here, despite the fact that women had signiﬁcantly lower levels
of DHEA(S). Population cohorts show controversial data regarding
the inﬂuence of gender in the association between DHEA(S) and
depression. Low DHEA(S) levels are associated to poor health in
men  (Tilvis et al., 1999; Goldman and Glei, 2007; Wong et al., 2011;
Michikawa et al., 2013), while others ﬁnd an association in women
(Yaffe et al., 1998; Morrison et al., 2000; Haren et al., 2007), and
others in neither (Glei et al., 2004; Hsu et al., 2009; Phillips et al.,
2011; ó Hartaigh et al., 2012, Hu et al., 2015). Mazat et al. (2011)
found low DHEA(S) levels to be associated with mortality in men,
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ut depressive symptomatology was only associated with women.
ichikawa et al. (2013) found an association between depressive
ymptoms in men, but not in women, while Berr et al. (1996) found
he inverse. Several studies only investigated associations exclu-
ively in one gender (men only, T’sjoen et al., 2005; Wong et al.,
011) (women only, Yaffe et al., 1998; Barrett-Connor et al., 1999;
aren et al., 2007).
One hypothesis to why our results differ from others may
e ethnical composition of our sample. A recent meta-analysis
espite concluding that DHEA(S) is associated with clinical major
epression (Hu et al., 2015), did not ﬁnd similar associations
n Caucasians or Asians in ethnicity-stratiﬁed analysis. Morrison
t al. (2001) has described racial differences among the rela-
ionship between DHEA(S) levels and depressive symptoms. In
ur sample, non-white women had signiﬁcantly lower levels of
HEA(S) as compared to white women (non-white 1.39 ± 0.15,
hite 1.85 ± 0.029, p = 0.05, n = 32); whereas there was no differ-
nce between white and non-white men. We  could not ﬁnd an
ssociation of depressive symptoms and DHEA(S) in non-white
eople however lack of power is an issue. Morsink et al. (2007)
eported a difference in the levels of testosterone between white
nd black women. DHEA is biotransformed to testosterone, and
his hormone improves depressive symptoms (Zarrouf et al., 2009).
HEA has also shown to induce pain acutely, but to have antinoci-
eptive action in the long-term, an effect partly related to analgesic
ffects of testosterone (Kibaly et al., 2008). Unfortunately, sex dif-
erences in analgesic effects might be relevant, but could not be
nvestigated here. Diet may  also be another explanation. DHEA(S)
s a precursor of estrogen and androgens. Countries that consume
ore soy-based products may  contribute to extra sources of estro-
en in women. DHEA(S) and soy diet is inversely associated with
epressive symptoms, perhaps due to the role of increased estro-
en levels on mental wellbeing (Nagata et al., 2000). Adjustments
or chronic illnesses may  also be relevant to explain differences
n ﬁndings. In stratiﬁed analysis by chronic illnesses, DHEA(S) was
ssociated to depression cross-sectionally in our sample only in
omen who were chronically ill (full-adjusted B = 3.021, p = 0.003).
ther reasons for the differences are not clear. Direct compar-
sons between the levels of DHEA(S) are difﬁcult as differences in
ocial, demographic, health behaviors and characteristics, culture
nd environment could inﬂuence DHEA(S)levels.
.3. Contribution of health characteristics and behavior
In our analysis, health characteristics and behaviors reduced the
ssociation, which in our baseline cross-sectional analysis became
on-signiﬁcant. One explanation might be that common mental
ealth disorder is a consequence of lower DHEA(S) resulting from
hronic pain, and disability associated with physical illness. In fact,
here is evidence showing that chronic stress diminishes DHEA(S)
evels (Lennartsson et al., 2015). In this sense, chronic illnesses
ight affect hippocampal brain cells and lymphocytes to become
ore vulnerable to the cytotoxic and modulatory effects of glu-
ocorticoids with age (Kimonides et al., 1999). Moreover, chronic
llnesses can lead to a degenerative change that may  be explained
y a decline in DHEA (McEwen et al., 1997; Bauer, 2008; Bauer
t al., 2009). Another explanation might be that DHEA(S) acts as
 risk factor to inﬂuence both psychological and physical health,
n a common cause hypothesis. In this study, we  could not dis-
ect these mechanisms as DHEA(S) was only collected at baseline.
he reason as to why chronic illnesses decrease the association
etween DHEA(S) and depression is not clear. Conﬂicting informa-
ion is observed in the literature. DHEA(S) has been associated with
hysical illness, and with frailty in the elderly, but a positive asso-
iation between DHEA(S) and cognitive impairment was  observed
n women only (Morrison et al., 2000).endocrinology 64 (2016) 40–46
In our study, health behaviors further reduced the cross-
sectional association between depressive symptoms and DHEA(S).
Disputed information is observed in the literature regarding the
inﬂuence of these covariates in the DHEA(S) and depression rela-
tionship. Smoking did not modify DHEA(S) levels in the study
of Chehab et al. (2007), whilst other studies report smoking
decreases DHEA(S) levels (Orentreich et al., 1992 Hsiesh et al.,
1998). Obesity has shown to present an inverse association to
DHEA(S) levels (Tchernof and Labrie, 2004). Although, one study
in major depressed patients reported that neither smoking nor
BMI  affect DHEA(S) and depression association (Markopoulou et al.,
2009). Some studies have demonstrated that alcohol consumption
increases DHEA(S) levels (Dorgan et al., 2001; Sierksma et al., 2004);
this effect might be dependent on the type of alcoholic drink, as
Hirko et al. (2014) observed a positive correlation with beer intake,
but not with other alcoholic drinks. Physical exercise was  observed
to increase DHEA levels, but DHEA(S) was increased only in women.
One hour after the exercise, hormone levels returned to values prior
to exercise (Heaney et al., 2013). Different results between DHEA
and DHEA(S) might occur once stimulus activating sympathetic
nervous system could affect DHEA sulfatase or sulfotransferase,
thus altering DHEA(S) levels (Kizildere et al., 2003). Besides, body
fat distribution is also a possible bias of exercise that could explain
controversial data (Straub et al., 2008).
4.4. Mechanisms of association
The role of DHEA and/or DHEA(S) in relation to depression might
partially rely upon a relationship with cortisol (Mocking et al., 2015;
Sugaya et al., 2015). DHEA is produced in the adrenal cortex and has
a variety of physiological functions, including anti-glucocorticoid
effects (Maninger et al., 2009). There is preliminary evidence that
DHEA lower cortisol levels in the periphery, providing further sup-
port for the antiglucocorticoid effect of DHEA. Besides, DHEA acts
as an antagonist to cortisol by interacting with the glucocorticoid
receptor (Kimonides et al., 1999), and DHEA promotes neurogen-
esis by antagonizing corticosterone neurotoxicity (Karishma and
Herbert, 2002). Since persistently high levels of cortisol levels are
associated with increased risk of depression, DHEA may have neu-
roprotective effects in the brain diminishing the liability for cortisol
to damage neurons and decreasing the risk for psychopathology.
Moreover, DHEA may  also impacts depression directly. Admin-
istration of DHEA increases both DHEA and its sulphated form
without affecting cortisol levels (Wolkowitz et al., 1997), what
suggests speciﬁc roles attributed to both DHEA and DHEA(S) them-
selves. Studies with animal models show that treatment with DHEA
(Moriguchi et al., 2013) and/or DHEA(S) (Malkesman et al., 2009)
ameliorate depressive behavior via a direct action of DHEA stim-
ulation in sigma receptors (Maurice et al., 1996), which in turn
modulate noradrenergic and serotonergic neurotransmission. In
fact, DHEA(S) concentration in the brain is higher than its plasmatic
levels even after adrenalectomy and gonadectomy, emphasizing
the relevant roles of DHEA(S) as a neuromodulator (Maninger et al.,
2009).
4.5. Limitations
Our study has both strengths and limitations. We  used a
large representative community-dwelling sample of older men
and women, an internationally validated questionnaire speciﬁc
for depressive symptoms, a population where supplementation
of DHEA(S) is uncommon, and a prospective design. On the other
hand, we only assessed DHEA(S) once at baseline and thus cannot
further understand mediation/moderation effect of health behav-
iors. Lack of knowledge of current antidepressant use could create a
bias, although this seems unlikely to have had a substantial effect.
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nly 3% of our population reported having used antidepressants
n the last two years; levels of DHEA(S) also did not differ between
hose who had or not taken it in the past. Although we have adjusted
or depression at baseline on our prospective analysis, we  cannot
xclude that reverse causation (impact of disease on DHEA(S)) does
ot play a role as individuals with depressive symptoms prior to the
ate of collection could have had lower levels of DHEA(S). Finally, it
s possible that in our study what we show is a conservative account
f the real association due to selection bias. People who  gave blood
ere more likely to be healthier than those who did not.
.6. Conclusions
Our ﬁndings provide evidence that lower DHEA(S) levels pre-
ict incident depressive symptoms in both men  and women. Future
esearch is needed to further examine whether DHEA(S) levels may
e used to identify those who would particularly beneﬁt from tar-
eted prophylactic treatment, and to further understand the role
f gender.
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